Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Elite Pharma Inc (OP: ELTP )

0.4950 -0.0200 (-3.88%)
Streaming Delayed Price Updated: 10:48 AM EST, Nov 7, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Elite Pharma Inc

< Previous 1 2 Next >
Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Second Quarter 2025 Financial Results on November 15, 2024
Northvale, New Jersey--(Newsfile Corp. - November 7, 2024) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty... 
Via Newsfile
Exposures Product Safety
Elite Pharmaceuticals' Generic Adderall(R) Receives Marketing Approval from the Israeli Ministry of Health
Northvale, New Jersey--(Newsfile Corp. - October 10, 2024) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty... 
Via Newsfile
Exposures Product Safety
Elite Pharmaceuticals Announces Commercial Launch of Acetaminophen and Codeine Phosphate Tablets
Northvale, New Jersey--(Newsfile Corp. - October 7, 2024) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company... 
Via Newsfile
Elite Pharmaceuticals Announces Commercial Launch of Generic Methotrexate Sodium
Northvale, New Jersey--(Newsfile Corp. - August 27, 2024) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty... 
Via Newsfile
Elite Pharmaceuticals, Inc. Reports Financial Results for Third Quarter of Fiscal Year 2024 ended December 31, 2023 and Provides Conference Call Information
Via ACCESSWIRE
Elite Pharmaceuticals, Inc. Reports Financial Results for Second Quarter of Fiscal Year 2024 ended September 30, 2023 and Provides Conference Call Information
Via ACCESSWIRE
Elite Pharmaceuticals, Inc. Reports Financial Results for First Quarter of Fiscal Year 2024 ended June 30, 2023 and Provides Conference Call Information
Via ACCESSWIRE
Elite Pharmaceuticals, Inc. Reports Financial Results for the First Quarter of Fiscal Year 2025 Ended June 30, 2024 and Provides Conference Call Information
Northvale, New Jersey--(Newsfile Corp. - August 14, 2024) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty... 
Via Newsfile
Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss First Quarter 2025 Financial Results on August 15, 2024
Northvale, New Jersey--(Newsfile Corp. - August 9, 2024) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty... 
Via Newsfile
Elite Pharmaceuticals, Inc. Reports Financial Results for the Fiscal Year Ended March 31, 2024 and Provides Conference Call Information
Northvale, New Jersey--(Newsfile Corp. - July 1, 2024) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty... 
Via Newsfile
Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Fiscal Year 2024 Financial Results on July 2, 2024
Northvale, New Jersey--(Newsfile Corp. - June 26, 2024) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty... 
Via Newsfile
Exposures Product Safety
Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss First Quarter 2024 Financial Results on August 15, 2023
Via ACCESSWIRE
Elite Pharmaceuticals, Inc. Reports Financial Results for the Fiscal Year Ended March 31, 2023 and Provides Conference Call Information
Via ACCESSWIRE
Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Fiscal Year 2023 Financial Results on June 30, 2023
Via ACCESSWIRE
Elite Pharmaceuticals Receives FDA Approval for Generic Methotrexate
Via ACCESSWIRE
Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Third Quarter 2024 Financial Results on February 15, 2024
Via ACCESSWIRE
Elite Pharmaceuticals Files ANDA with US FDA to Market Central Nervous System Stimulant
Via ACCESSWIRE
Elite Pharmaceuticals Announces First Product Shipment of Generic Adderall XR(R) to Marketing Partner Prasco, LLC
Via ACCESSWIRE
Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Second Quarter 2024 Financial Results on November 15, 2023
Via ACCESSWIRE
Elite Pharmaceuticals, Inc. Reports Financial Results for the Third Quarter of Fiscal Year 2023 ended December 31, 2022 and Provides Conference Call Information
Via ACCESSWIRE
Elite Pharmaceuticals, Inc. Reports Financial Results for the Second Quarter of Fiscal Year 2023 Ended September 30, 2022 and Provides Conference Call Information
Via ACCESSWIRE
Elite Pharmaceuticals Reports Positive Results from a Pivotal Bioequivalence Study
Via ACCESSWIRE
Elite Pharmaceuticals Files ANDA with US FDA to Market Opiate Analgesic Product
Via ACCESSWIRE
Elite Pharmaceuticals, Inc. Appoints Carter Ward as Chief Financial Officer
Via ACCESSWIRE
Elite Pharmaceuticals Reports Positive Results from a Pivotal Bioequivalence Study
Via ACCESSWIRE
Elite Pharmaceuticals, Inc. Appoints Mark Pellegrino as Chief Financial Officer
Via ACCESSWIRE
Elite Pharmaceuticals Files ANDA with US FDA to Market Antimetabolite Product
Via ACCESSWIRE
Elite Pharmaceuticals Reports Positive Results from a Pivotal Bioequivalence Study
Via ACCESSWIRE
Elite Pharmaceuticals Files ANDA with US FDA to Market Dopamine Agonist
Via ACCESSWIRE
Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Second Quarter 2023 Financial Results on November 15, 2022
Via ACCESSWIRE
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.